March 3, 2026Open Access

Hepatic steatosis and fibrosis are associated with metabolic factors rather than endocrine therapy in breast cancer patients

Key Points

Hepatic steatosis and fibrosis are significantly associated with metabolic factors in breast cancer patients, not endocrine therapy.
Over half the patients showed signs of steatosis, while approximately 10% had advanced fibrosis.
This analysis includes a two-year follow-up, revealing no changes in liver stiffness with continual hormone therapy.
Implications suggest focusing on metabolic management may enhance patient outcomes in breast cancer care.

Abstract

Over half of the participants had SLD, with advanced fibrosis in ~10%. Metabolic factors were independently associated with SLD development and progression, regardless of hormone therapy exposure. Patients in continuous use of endocrine therapy had no dynamic changes in liver stiffness after 24 months of follow-up.

Hepatic steatosis and fibrosis are associated with metabolic factors rather than endocrine therapy in breast cancer patients

Key Points

Abstract

Cite This Study